The Wall Street Journal reports that Pharmacylics today announced that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory CLL/SLL, has been achieved ahead of schedule and enrollments are now officially closed:
online.wsj.com/article/PR-C...
Good to see patients being thanked too!
It will be interesting to see the outcomes of this larger trial.
Neil
UK first to trial AstraZeneca 'antibody cocktail' aimed at non-vaccine patients
First day on Clinical Trial Ibrutinib / Venetoclax 
UK NICE Approves Ibrutinib +Venetoclax for First Line treatment for ALL Patients from today
Ibrutinib denied to new patients
